Product Code: A14012
The finasteride market valued for $362.11 million in 2021 and is estimated to reach $546.72 million by 2031, exhibiting a CAGR of 4.2% from 2022 to 2031.
Finasteride is a medication used primarily for the treatment of male pattern baldness and benign prostatic hyperplasia (BPH). It works by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to hair loss and prostate enlargement. The major factors driving the growth of the finasteride market include rise in prevalence of hair loss and benign prostatic hyperplasia (BPH), as well as surge in awareness about the benefits of finasteride treatment. For instance, article published in National Library of Medicine 2021, stated that, male pattern baldness affects up to 2% of general population. This rise in male pattern baldness is anticipated to drive the growth of the market.
In addition, a rise in prevalence of benign prostatic hyperplasia (BPH) is expected to fuel the market growth. For instance, according to an article published in Lancet Healthy Longevity Journal 2022, a total of 94 million prevalent cases of benign prostatic hyperplasia (BPH) were reported in 2019 across the globe. Further, as the global population continues to age, there is a witnessed increase in the incidence of benign prostatic hyperplasia (BPH) and other prostate-related conditions. This has led to a rise in demand for medications such as finasteride, which help manage benign prostatic hyperplasia (BPH) symptoms. Thus, a rise in geriatric population is anticipated to drive the growth of the market.
Further, the availability of generic types of finasteride has contributed to the growth of the market, as it has made the medication affordable and accessible to a wider population. For instance, Dr. Reddy's Laboratories Ltd., offers finasteride tablets in generic type, thus, such availability of generic type of finasteride is expected to propel market expansion. Moreover, a rise in the number of key players offering finasteride in branded and generic form is expected to fuel the growth of the market. For instance, key players such as Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd., offer finasteride in branded and generic versions such as PROSCAR (Finasteride). Thus, the presence of such key players offering finasteride fuels the growth of the market.
Furthermore, rise in disposable income also drives the market growth owing to increased demand for medications that improve physical appearance, such as finasteride for male pattern hair loss. In addition, individuals may be willing to invest in treatments that can help them look and feel better, with an increase in disposable income.
However, alternative treatments for male pattern baldness and benign prostatic hyperplasia (BPH), such as hair transplant surgery and availability of other alternate medications are the factors which restrain the growth of the finasteride market. In addition, the absence of favorable reimbursement policies is also expected to constrain the growth of the market. Further, rise in demand for finasteride and increase in awareness about finasteride for male pattern baldness offers lucrative opportunities to key players of the finasteride market.
The finasteride market is segmented into application, type, distribution channel and region. On the basis of application, the market is bifurcated into benign prostatic hyperplasia (BPH), and male pattern baldness. On the basis of type, the market is categorized into branded and generic. On the basis of distribution channel, the market is segregated into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global finasteride market include: Alkem Laboratories Ltd, Dr. Reddy's Laboratories Ltd., HETERO LABS LIMITED, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Organon & Co., Cipla Ltd., and Aurobindo Pharma.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the finasteride market analysis from 2021 to 2031 to identify the prevailing finasteride market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the finasteride market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global finasteride market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Benign Prostatic Hyperplasia (BPH)
- Male pattern baldness
By Type
By Distribution Channel
- Hospital Pharmacies
- Online Providers
- Drug Stores and Retail Pharmacies
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Alkem Laboratories Ltd
- HETERO LABS LIMITED
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Organon & Co.
- Aurobindo Pharma
- Cipla Ltd
- Dr. Reddy's Laboratories Ltd.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of male pattern baldness
- 3.4.1.2. Rise in adoption of finasteride for benign prostatic hyperplasia (BPH)
- 3.4.1.3. Increase in adherence of finasteride for treatment of BPH and male pattern baldness
- 3.4.2. Restraints
- 3.4.2.1. Side effects associated with finasteride
- 3.4.2.2. Competition from other medications and availability of alternate medicine
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: FINASTERIDE MARKET, BY APPLICATION
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Benign Prostatic Hyperplasia (BPH)
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Male pattern baldness
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
CHAPTER 5: FINASTERIDE MARKET, BY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Branded
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Generic
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
CHAPTER 6: FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
CHAPTER 7: FINASTERIDE MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Application
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Application
- 7.2.5.1.3. Market size and forecast, by Type
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Application
- 7.2.5.2.3. Market size and forecast, by Type
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Application
- 7.2.5.3.3. Market size and forecast, by Type
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Application
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Application
- 7.3.5.1.3. Market size and forecast, by Type
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Application
- 7.3.5.2.3. Market size and forecast, by Type
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Application
- 7.3.5.3.3. Market size and forecast, by Type
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Application
- 7.3.5.4.3. Market size and forecast, by Type
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Application
- 7.3.5.5.3. Market size and forecast, by Type
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Application
- 7.3.5.6.3. Market size and forecast, by Type
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Application
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Application
- 7.4.5.1.3. Market size and forecast, by Type
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Application
- 7.4.5.2.3. Market size and forecast, by Type
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Application
- 7.4.5.3.3. Market size and forecast, by Type
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Application
- 7.4.5.4.3. Market size and forecast, by Type
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Application
- 7.4.5.5.3. Market size and forecast, by Type
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Application
- 7.4.5.6.3. Market size and forecast, by Type
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Application
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Application
- 7.5.5.1.3. Market size and forecast, by Type
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Application
- 7.5.5.2.3. Market size and forecast, by Type
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Application
- 7.5.5.3.3. Market size and forecast, by Type
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Application
- 7.5.5.4.3. Market size and forecast, by Type
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
- 9.1. Alkem Laboratories Ltd
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Dr. Reddy's Laboratories Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. HETERO LABS LIMITED
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.4. Intas Pharmaceuticals Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Merck & Co., Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Organon & Co.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Cipla Ltd
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Aurobindo Pharma
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance